We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Questions and Conundrums: What Is the Future of ADCs in HR+/HER2-Low MBC?
Erica L. Mayer, MD, MPH
Sarah Sammons, MD
Which Resected Stage II Melanoma Patients Benefit from Adjuvant ICI Therapy?
Nikhil I. Khushalani, MD
Who Is the Best Candidate for Sequencing Trastuzumab Detruxtecan (T-DXd) First?
What Are the Clinical and Therapeutic Implications of the Evolving HER2 Testing Landscape?
Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL
John P. Leonard, MD
Matthew J. Matasar, MD
Alex Herrera, MD
Kami Maddocks, MD
Alison J. Moskowitz, MD
Sarah Rutherford, MD
Late-Stage Bispecifics and ADCs in DLBCL
Patient Selection for ADCs in First-Line DLBCL
Bispecific Antibodies in FL
Application of Data from the ECHELON-1 Trial
Individualizing Frontline Treatment
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
Antibody-Drug Conjugates in FL
NCCN Guideline Updates in DLBCL
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
Case 5: Is There a Role for IO-Based Therapy in KRAS-Mutated NSCLC? What About Patients With Co-mutations in STK11 or KEAP1?
Charu Aggarwal, MD, MPH
Joshua E. Reuss, MD
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education